drugset / Trial / NCT06556862
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
NaSingle-groupOpen-labelTreatment
Summary
A phase II study to explore the efficacy and safety of dalpiciclib plus HDACi in HR+/HER2- advanced breast cancer after the failure of CDK4/6 inhibitor therapy.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | 100 mg | — |
| Subject | Enitinostat | Unknown | 5 mg | — |
| Subject | Tucidinostat | Small molecule | 25 mg | — |